Ocular melanoma: what's new?

被引:17
作者
Leyvraz, Serge [2 ]
Keilholz, Ulrich [1 ]
机构
[1] Charite, Dept Hematol & Med Oncol, Comprehens Ctr, Berlin, Germany
[2] Univ Lausanne Hosp, Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland
关键词
GNA11; GNAQ; intra-hepatic treatments; new molecular therapies; uveal melanoma; INTRAARTERIAL HEPATIC FOTEMUSTINE; GENE-EXPRESSION ANALYSIS; RISK UVEAL MELANOMA; PHASE-II TRIAL; LIVER METASTASES; CHEMOEMBOLIZATION TACE; GROWTH-FACTOR; SURVIVAL; EXPERIENCE; MUTATIONS;
D O I
10.1097/CCO.0b013e32834ff069
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review The purpose of this review was to summarize available data on uveal melanoma biology and treatment in order to provide the medical community with a basic reference that would help to make further progress in this rare disease, which remains difficult to treat. Recent findings The most relevant recent findings driving current clinical developments are in the elucidation of uveal melanoma genetics and genomics. The key driving mutations - that differ completely from cutaneous melanoma - have been identified. Based on the novel insights into key signaling pathways, the first clinical trials with targeted treatments have been implemented. However, systemic and regional chemotherapy approaches as well as other regional treatment modalities for liver metastases are also a major part of the current treatment armamentarium and are prospectively being evaluated. Summary In summary, the recent biological findings and the creation of a series of clinical trials underscore how the international community is able to perform relevant advances in an extremely rare disease.
引用
收藏
页码:162 / 169
页数:8
相关论文
共 94 条
[1]   MET Oncogene Inhibition as a Potential Target of Therapy for Uveal Melanomas [J].
Abdel-Rahman, Mohamed H. ;
Boru, Getachew ;
Massengill, James ;
Salem, Manar M. ;
Davidorf, Frederick H. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (07) :3333-3339
[2]  
Alexander HR, 2000, CLIN CANCER RES, V6, P3062
[3]  
Alexander HR, 2003, CLIN CANCER RES, V9, P6343
[4]  
All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1
[5]  
Antoine Radcliffe A, 2011, J Extra Corpor Technol, V43, P30
[6]   Expression of somatostatin receptors in uveal melanomas [J].
Ardjomand, N ;
Ardjomand, N ;
Schaffler, G ;
Radner, H ;
El-Shabrawi, Y .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (03) :980-987
[7]   Effectiveness of Treatments for Metastatic Uveal Melanoma [J].
Augsburger, James J. ;
Correa, Zelia M. ;
Shaikh, Adeel H. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (01) :119-127
[8]   Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma [J].
Bauer, J. ;
Kilic, E. ;
Vaarwater, J. ;
Bastian, B. C. ;
Garbe, C. ;
de Klein, A. .
BRITISH JOURNAL OF CANCER, 2009, 101 (05) :813-815
[9]  
BEDIKIAN AY, 1995, CANCER, V76, P1665, DOI 10.1002/1097-0142(19951101)76:9<1665::AID-CNCR2820760925>3.0.CO
[10]  
2-J